Quick Answer
Rallybio Corp reported Total Revenue of $858.0 thousand for fiscal year 2025.
Rallybio Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $858.0K +34.9% |
$636.0K | — | — | — | — |
| Net Income | -$8.98M +84.5% |
-$57.77M +22.5% |
-$74.56M -11.9% |
-$66.65M -41.8% |
-$47.01M -77.8% |
-$26.45M |
| Diluted EPS | -$1.59 +85.0% |
-$10.61 -476.6% |
-$1.84 +12.0% |
-$2.09 -13.6% |
-$1.84 | — |
| Total Assets | $62.26M -8.6% |
$68.11M -41.1% |
$115.62M -35.9% |
$180.44M -1.0% |
$182.19M +28.4% |
$141.86M |
| Cash and Equivalents | $31.37M +125.7% |
$13.90M -43.2% |
$24.49M -57.0% |
$56.96M -67.5% |
$175.33M +25.0% |
$140.23M |
| Stockholders Equity | $57.96M -6.0% |
$61.65M -41.9% |
$106.18M -37.3% |
$169.32M -3.6% |
$175.60M +29.1% |
$136.00M +706.7% |
| R&D Expense | $19.60M -52.8% |
$41.51M -22.5% |
$53.54M +31.6% |
$40.69M +51.2% |
$26.91M +52.6% |
$17.63M |
| Operating Income | -$33.06M +45.3% |
-$60.50M +23.4% |
-$78.93M -16.3% |
-$67.88M -48.7% |
-$45.65M -80.4% |
-$25.30M |
| Shares Outstanding | 5.28M +1.8% |
5.19M -86.3% |
37.83M -0.0% |
37.84M +17.8% |
32.13M +37.2% |
23.41M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $212.0K | -29.1% | +0.0% |
| Net Income | September 30, 2025 | $16.02M | +239.7% | +265.1% |
| Diluted EPS | September 30, 2025 | $0.36 | +238.5% | +263.6% |
| Total Assets | September 30, 2025 | $67.66M | -14.4% | +32.7% |
| Cash and Equivalents | September 30, 2025 | $32.12M | +26.9% | +240.1% |
| Stockholders Equity | September 30, 2025 | $63.03M | -11.0% | +37.1% |
| R&D Expense | September 30, 2025 | $4.14M | -49.7% | -31.8% |
| Operating Income | September 30, 2025 | -$6.92M | +42.6% | +31.1% |
| Shares Outstanding | September 30, 2025 | 41.94M | +1.1% | +0.5% |
- Rallybio Corp reported Total Revenue of $858.0 thousand for fiscal year 2025.
- Rallybio Corp showed an increase of +34.9% in Total Revenue compared to the prior fiscal year.
- Rallybio Corp reported Net Income of -$8.98 million for fiscal year 2025.
- Rallybio Corp showed an increase of +84.5% in Net Income compared to the prior fiscal year.
- Rallybio Corp reported Diluted EPS of $1.59 per share (loss) for fiscal year 2025.
- Rallybio Corp showed an increase of +85.0% in Diluted EPS compared to the prior fiscal year.
- Rallybio Corp reported Total Assets of $62.26 million for fiscal year 2025.
- Rallybio Corp showed a decrease of -8.6% in Total Assets compared to the prior fiscal year.
- Rallybio Corp reported Cash and Equivalents of $31.37 million for fiscal year 2025.
- Rallybio Corp showed an increase of +125.7% in Cash and Equivalents compared to the prior fiscal year.
- Rallybio Corp reported Stockholders Equity of $57.96 million for fiscal year 2025.
- Rallybio Corp showed a decrease of -6.0% in Stockholders Equity compared to the prior fiscal year.
- Rallybio Corp reported R&D Expense of $19.60 million for fiscal year 2025.
- Rallybio Corp showed a decrease of -52.8% in R&D Expense compared to the prior fiscal year.
- Rallybio Corp reported Operating Income of -$33.06 million for fiscal year 2025.
- Rallybio Corp showed an increase of +45.3% in Operating Income compared to the prior fiscal year.
- Rallybio Corp reported Shares Outstanding of 5.28 million shares for fiscal year 2025.
- Rallybio Corp showed an increase of +1.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: